NEGATIVE MODULATION OF AUTOPHAGY PATHWAY BY SURVIVIN/BIRC5 IN THE RESISTANCE OF PANCREAS ADENOCARCINOMA CELLS

MAXIMILIANO A. DIAZ; MARIA NOÉ GARCIA; DANIELA L. PAPADEMETRIO; MARTIN FERNANDEZ-ZAPICO; ELIDA ALVAREZ; DANIEL GRASSO

Mar del Plata

Congreso; Reunión Anual de Biociencias 2022; 2022

Sociedad Argentina de Investigación Clínica

Gemcitabine, the standard chemotherapy for pancreatic ductal adenocarcinoma (PDAC), induces low levels of apoptosis partially due to autophagy induction during the treatment. Autophagy inhibition allows apoptosis triggered by inhibitors of MAPKs pathway. In this context, a relationship between Survivin/BIRC5, from the IAPs family, and autophagy is observed. The aim of this work was to evaluate the modulation autophagy mediated by Survivin in PDAC cells. The MAPKs inhibitor U0126 increases Survivin (p